Scynexis scynexis.com


Public lists: Pharma Startups (4732)

Scynexis is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. The company is developing its lead product candidate, SCY-078, as a novel oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, Scynexis has clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases, as well...Show all

Scynexis is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. The company is developing its lead product candidate, SCY-078, as a novel oral...Show all

Company (IPO / Went public)

Phone: 919-544-8600

Fax:

3501 C Tricenter Boulevard

Durham, 27713
North Carolina, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Scynexis $135.1M May 2, 2014
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Scynexis Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Alta PartnersVenture CapitalSan Francisco, California, United StatesSeries C - III, Series C
Aventis Venture ActivitiesCorporate VentureFranceSeries C, Series A
GenaventVenture CapitalLondon, England, United KingdomOther Investors
Burrill & CompanyVenture CapitalSan Francisco, California, United StatesSeries D, Series C - III, Series C - II, Series C
See all 13 investors

Competitors

Company Status Description Investors
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Macrocyclic peptides Jun 05, 2009 Jul 28, 2015 Patent
Processes for isolation and purification of enfumafungin Aug 30, 2010 Mar 18, 2014 Patent
Antifungal agents Sep 25, 2008 Jul 17, 2012 Patent
Antifungal agents Mar 29, 2007 Jan 04, 2011 Patent
Antiviral macrocycles Oct 21, 2013 Application
See all 6 patents